Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05748873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Promising ROd-cone DYstrophy Gene therapY

Study acronym: PRODYGY
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2025 to Feb 2027v6 Show 6 more changesShow less
    • Primary endpoint revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 2030 to Feb 2031
    • Secondary endpoints revised (12)
    • Site details revised at 6 of 6 sites
    • Eligibility criteria shortened, about 5 words
  2. Study sites: 4 to 6
    • Primary completion date: Mar 2025 to Sep 2025
    • Study completion date: Mar 2029 to Sep 2030
    v5
  3. Study sites: 2 to 4
    • Eligibility criteria expanded, about 68 words
    • Secondary endpoints: 13 to 12
    v4
  4. Start date changed from estimate of Apr 2023 to Apr 12, 2023
    • Study sites revised (2)
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 2023 to Apr 2023
    • Study sites revised (2)
    • Eligibility criteria expanded, about 3 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).
Trial Details
NCT Number NCT05748873
Lead Sponsor SparingVision
Conditions
(from sponsor)		 Retinitis Pigmentosa
Related terms Cone-Rod Dystrophies, Eye Diseases, Retinal Degeneration, Retinal Diseases, Retinal Dystrophies, Retinitis Pigmentosa
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov